Sign in to view content

ZETA-1 Phase 2 Trial Efficacy Results for APX3330 a Novel Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy

David R Lally, MD

Video
Published 2023

Related

Barriers to implentation of Teleretinal Diabetic Retinal Screening in a private practice setting.
Ramanath Bhandari, MD
On Demand Cases, Courses, and Papers
2019
Evaluation of Nonperfusion Area and Other Vascular Metrics by Widefield SS-OCTA as Biomarkers of Diabetic Retinopathy Severity
John B. Miller, MD
Annual Meeting Talks
2021
Aflibercept 8 mg for Diabetic Macular Edema: 2-Year Results of the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Annual Meeting Talks
2023

Category: Diabetic Retinopathy

See more